Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series

Ítems similars

• Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series
  per: Yang, Stephen Su, et al.
  Publicat: (2020)
• Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
  per: Rajendram, Prabalini, et al.
  Publicat: (2021)
• Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
  per: Liu, Danfei, et al.
  Publicat: (2020)
• Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
  per: Price, Christina C., et al.
  Publicat: (2020)
• Care of critically ill pregnant patients with coronavirus disease 2019: a case series
  per: Hirshberg, Adi, et al.
  Publicat: (2020)